Research output per year
Research output per year
Scheelevägen, Medicon Village, hus 404
Lund
Sweden
Recently the treatment landscape of metastatic melanoma has changed dramatically with introduction of targeted therapy and novel immune checkpoint blockade agents. However, acquired resistance to targeted therapy and relatively low response rates to immune therapy poses a major problem. Thus, increased knowledge in melanoma biology and identification of novel therapeutic strategies is a necessity to further increase survival. We posit that using human tumor molecular data as a foundation for functional studies will lead us to novel insights about the fundamental biology of melanoma as well as provide us with inspiration for designing novel therapeutic strategies. Accordingly, our research program is focused on genomic tumor biology and the subsequent functional elucidation of biological mechanisms. We are also part of international melanoma consortia such as MELGEN (www.melgen.org) and GenoMEL (www.genomel.org).
Person
Person
Person
Research output: Contribution to journal › Article › peer-review
Research output: Contribution to journal › Article › peer-review
Research output: Contribution to journal › Article › peer-review
Jönsson, G. B. (PI)
Mrs. Berta Kamprad's Cancer Foundation, Mats Paulssons stiftelse
2025/01/01 → 2027/03/01
Project: Research
Jönsson, G. B. (PI)
Mrs. Berta Kamprad's Cancer Foundation
2024/01/01 → 2028/03/01
Project: Research
Svensson, M. (Researcher), Jirström, K. (Supervisor) & Jönsson, G. B. (Assistant supervisor)
2022/01/01 → 2026/01/01
Project: Dissertation
Nielsen, K. (Joint first/primary/lead supervisor), Jönsson, G. B. (Second supervisor), Isaksson, K. (Supervisory team member) & Ingvar, Å. (Third supervisor)
Activity: Examination and supervision › Supervision
Pereira, C.-F. (First/primary/lead supervisor) & Jönsson, G. B. (Second supervisor)
Activity: Examination and supervision › Supervision of PhD students